Nexalin Technology (NXL) Expected to Release Quarterly Earnings on Wednesday

Nexalin Technology (NASDAQ:NXL – Get Free Report) is expected to post its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect Nexalin Technology to post earnings of ($0.10) per share and revenue of $0.09 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 7:00 AM ET.

Nexalin Technology (NASDAQ:NXL – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($3.00) by ($0.30). Nexalin Technology had a negative net margin of 4,141.94% and a negative return on equity of 278.24%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.09 million.

Get Nexalin Technology alerts:

Nexalin Technology Trading Down 3.6%

NASDAQ:NXL opened at $7.23 on Tuesday. Nexalin Technology has a 1-year low of $6.25 and a 1-year high of $60.00. The firm has a fifty day simple moving average of $11.08 and a 200 day simple moving average of $12.13. The stock has a market capitalization of $159.35 million, a PE ratio of -15.06 and a beta of 4.00.

Institutional Trading of Nexalin Technology

Institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new stake in shares of Nexalin Technology in the third quarter valued at approximately $57,000. Renaissance Technologies LLC increased its holdings in shares of Nexalin Technology by 119.2% during the 4th quarter. Renaissance Technologies LLC now owns 122,100 shares of the company’s stock worth $68,000 after acquiring an additional 66,400 shares during the last quarter. Geode Capital Management LLC raised its stake in Nexalin Technology by 23.4% in the 4th quarter. Geode Capital Management LLC now owns 150,274 shares of the company’s stock valued at $84,000 after acquiring an additional 28,454 shares during the period. Finally, PEAK6 LLC bought a new stake in Nexalin Technology in the 4th quarter valued at $266,000. Institutional investors own 0.65% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Research Report on Nexalin Technology

About Nexalin Technology

(Get Free Report)

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.

Featured Stories

• Five stocks we like better than Nexalin Technology
• Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
• Insiders Are Betting Big on These 3 Healthcare Stocks
• 3 Stocks for Investors Who Still Believe Cash Is King
• Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.